Biomedical Engineering Reference
In-Depth Information
56. Dyer D, Callanan D, Bochow T, Abraham P,
Lambert HM, Lee SY et al (2009) Clinical
evaluation of the safety and efficacy of
preservative-free triamcinolone (triesence [tri-
amcinolone acetonide injectable suspension]
40 mg/ml) for visualization during pars plana
vitrectomy. Retina 29(1):38-45
58. Bardak Y, Cekic O, Tig SU (2006) Compari-
son of ICG-assisted ILM peeling and
triamcinolone-assisted posterior vitreous
removal in diffuse diabetic macular oedema.
Eye 20(12):1357-1359
59. Peyman GA, Cheema R, Conway MD, Fang T
(2000) Triamcinolone acetonide as an aid to
visualization of the vitreous and the posterior
hyaloid during pars plana vitrectomy. Retina
20(5):554-555
60. Clark AF (2007) Mechanism of action of the
angiostatic cortisene anecortave acetate. Surv
Ophthalmol 52(Suppl 1):S26-S34
61. Blei F, Wilson EL, Mignatti P, Rifkin DB
(1993) Mechanism of action of angiostatic
steroids: suppression of plasminogen activator
activity via stimulation of plasminogen activa-
tor
64. BenEzra D, Griffin BW, Maftzir G, Sharif NA,
Clark AF (1997) Topical formulations of novel
angiostatic steroids inhibit rabbit corneal neo-
vascularization. Invest Ophthalmol Vis Sci
38(10):1954-1962
65. Liu C, Gu X, Wang W-H, Bingaman D (2005)
Local delivery of anecortave acetate inhibits the
expression of retinal IGF-1/IGF-1 receptor in
the rat OIR model. Invest Ophthalmol Vis Sci
46(5):4135
66. Yang R, McCollum GW, Bingaman DP, Penn
JS (2005) The effect of anecortave acetate on
VEGF message and protein levels in hypoxic
muller cells and in rat OIR. Invest Ophthalmol
Vis Sci 46(5):4177
67. Russell SR, Hudson HL, Jerdan JA (2007)
Anecortave acetate for the treatment of exuda-
tive age-related macular degeneration-a review
of
clinical
outcomes.
Surv Ophthalmol
52(Suppl 1):S79-S90
68. Augustin A (2006) Anecortave acetate in the
treatment of age-related macular degeneration.
Clin Interv Aging 1(3):237-246
69. Stalmans I, Callanan DG, Dirks MS, Moster
MR, Robin AL, Van Calster J et al (2012)
Treatment of steroid-induced elevated intraoc-
ular pressure with anecortave acetate: a rando-
mized clinical trial. J Ocul Pharmacol Ther
28(6):559-565
70. Regillo CD, D'Amico DJ, Mieler WF, Schnee-
baum C, Beasley CH, Sullins GT (2007) Clini-
cal safety profile of posterior juxtascleral depot
administration of anecortave acetate 15 mg
suspension as primary therapy or adjunctive
therapy with photodynamic therapy for treat-
ment of wet age-related macular degeneration.
Surv Ophthalmol 52(Suppl 1):S70-S78
inhibitor
synthesis.
J Cell Physiol
155(3):568-578
62. DeFaller JM, Clark AF (2000) A new pharma-
cological treatment for angiogenesis. In: Taylor
HR (ed) Pterygium. Kugler Pub, The Hague,
Netherlands, pp 159-181
63. Penn JS, Rajaratnam VS, Collier RJ, Clark AF
(2001) The effect of an angiostatic steroid on
neovascularization in a rat model of retinopa-
thy of prematurity. Invest Ophthalmol Vis Sci
42(1):283-290
